Tecan launches rapid viral and pathogen characterization RNA-Seq library preparation solution for challenging sample types

Tecan has launched the Revelo RNA-Seq kit, offering end-to-end processing of human samples to enable complete viral RNA-Seq library preparation – including library quantification – in a single day.

This kit has been developed specifically to address the pathogen detection and characterization challenges currently faced by laboratories around the world and is ideally suited to NGS library preparation from a low input, patient-derived sample types, such as nasal swabs.

Revelo RNA-Seq offers a user-friendly solution for cost-effective, same-day library preparation by combining

an enhanced version of Tecan’s SPIA® (Single Primer Isothermal Amplification) technology with the company’s unique, fluorescence-based NuQuant® library quantification. Optimized to provide high sensitivity for degraded or low copy number viral RNA in human samples, it allows rapid, sensitive identification and characterization of pathogens.

This new kit has already been rigorously tested with a range of patient-derived samples containing pathogens, such as SARS-CoV-2 and other respiratory diseases. The automation-friendly kit has also been implemented on Tecan’s DreamPrep™ NGS workstation to offer a complete, automated solution for walkaway processing, helping to increase throughput and efficiency in busy labs.

The Revelo RNA-Seq kit was developed in response to an urgent need for faster, easier pathogen library preparation from low copy number or degraded sample types, such as nasal swabs. Optimized for enhanced human rRNA depletion, the kit offers ‘SPIA with a boost’ to ensure better sensitivity and reduced sequencing costs.”

Klaus Lun, Executive Vice President and Head of the Life Sciences Business Division at Tecan

To learn more about the Revelo RNA-Seq kit, go to www.tecan.com/viral-sequencing-at-the-limits-of-detection

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Tecan. (2020, December 02). Tecan launches rapid viral and pathogen characterization RNA-Seq library preparation solution for challenging sample types. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20201202/Tecan-launches-rapid-viral-and-pathogen-characterization-RNA-Seq-library-preparation-solution-for-challenging-sample-types.aspx.

  • MLA

    Tecan. "Tecan launches rapid viral and pathogen characterization RNA-Seq library preparation solution for challenging sample types". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20201202/Tecan-launches-rapid-viral-and-pathogen-characterization-RNA-Seq-library-preparation-solution-for-challenging-sample-types.aspx>.

  • Chicago

    Tecan. "Tecan launches rapid viral and pathogen characterization RNA-Seq library preparation solution for challenging sample types". News-Medical. https://www.news-medical.net/news/20201202/Tecan-launches-rapid-viral-and-pathogen-characterization-RNA-Seq-library-preparation-solution-for-challenging-sample-types.aspx. (accessed November 21, 2024).

  • Harvard

    Tecan. 2020. Tecan launches rapid viral and pathogen characterization RNA-Seq library preparation solution for challenging sample types. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20201202/Tecan-launches-rapid-viral-and-pathogen-characterization-RNA-Seq-library-preparation-solution-for-challenging-sample-types.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer